NFKB1 and central nervous system cancer: Similarly, combining CUDC-907, a dual PI3K/HDAC inhibitor, or DMAPT, an orally active NF-κB inhibitor, with irradiation sensitized glioma and NSCLC cells, respectively, by inhibiting DNA repair (77, 78).